Statement: In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. 
Primary_evidence: Outcome Measurement:    Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24   Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips. (BMD). Two X-ray beams with different energy levels are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.   Time frame: baseline, month 24 Results 1:    Arm/Group Title: Placebo   Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).   Overall Number of Participants Analyzed: 36   Mean (Standard Deviation)   Unit of Measure: Z-score  -0.075         (0.041) Results 2:    Arm/Group Title: Zometa   Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).   Overall Number of Participants Analyzed: 34   Mean (Standard Deviation)   Unit of Measure: Z-score  0.037         (0.042)